# SeedBench-Bio Model Response

## Metadata

- **Prompt variant:** blind
- **Prompt file:** prompts/claims/error_detection/blind.md
- **Model:**
provider: Anthropic
name: Claude Sonnet
thinking: medium
- **Task file:** benchmark_tasks/interpretation_claims/claim_stimulus.json
- **Ground truth file:** ground_truth/intepretation_claims/claims_ground_truth.json
- **Timestamp:** 2026-08-06 15:16:00
- **Temperature:** 0
## Prompt sent to model

I am a senior computational biologist at Roche. I am working on a project. My team member, who is also a senior computatational biologist, has made these conclusions based on our work in the lab. Can you help me summarize these results?

      "id": "C1",
      "title": "Glycolysis gene enrichment from a single surviving gene",
      "context": "Differential expression comparison, MB vs CPA. Number of genes tested: 5592. Glycolysis genes tested: 1 of 2 (only PFKFB3 of the two glycolysis genes, PFKP and PFKFB3, cleared the min.pct filter and appears in this comparison's DEG table). Results: glycolysis genes upregulated in MB: 0 out of 1 (p = 1.00, OR = 0). Glycolysis genes upregulated in CPA: 1 out of 1 (p = 0.276, OR = Inf). Enrichment table -- PFKP: MB N/A, CPA N/A. PFKFB3: MB not enriched, CPA enriched.",
      "claim": "Because the odds ratio is Inf and 1 of 1 tested glycolysis genes is upregulated in CPA, glycolysis genes are enriched in CPA."
    },
    {
      "id": "C2",
      "title": "PCA component assigned a biological label",
      "context": "PCA was run on a bulk RNA-seq expression matrix. PC1 explains 65% of total variance. No sample metadata (treatment/control labels, batch, sex, etc.) or gene loadings were examined.",
      "claim": "PC1 represents treatment effects."
    },
    {
      "id": "C3",
      "title": "GO enrichment result generalized to every gene in the pathway",
      "context": "GO enrichment was run on the DE gene list from a treatment vs control comparison. Top GO term: 'Immune response', FDR = 0.002.",
      "claim": "Every immune-related gene is upregulated in the treatment group."
    },
    {
      "id": "C4",
      "title": "Heatmap of top DE genes described as most highly expressed",
      "context": "A heatmap was generated showing the top 50 genes ranked by FDR (adjusted p-value) from a differential expression analysis.",
      "claim": "These are the 50 most highly expressed genes in the dataset."
    },
    {
      "id": "C5",
      "title": "Patient-driven clusters called novel cell subpopulations",
      "context": "scRNA-seq data from 3 patients were integrated and clustered without a batch-correction/integration step (no Harmony/CCA/RPCA run). UMAP shows 3 well-separated clusters. Cluster composition by patient of origin: Cluster 1 -- 98% Patient A, 1% Patient B, 1% Patient C. Cluster 2 -- 2% Patient A, 95% Patient B, 3% Patient C. Cluster 3 -- 3% Patient A, 4% Patient B, 91% Patient C.",
      "claim": "We identified three novel, biologically distinct cell subpopulations."
    },
    {
      "id": "C6",
      "title": "Strong correlation described as direct regulation",
      "context": "Co-expression analysis across 40 samples. Gene A (a transcription factor) and Gene B (a downstream pathway gene) show Pearson r = 0.85, p < 0.001. No perturbation, binding, or chromatin accessibility data were generated.",
      "claim": "Gene A directly regulates transcription of Gene B."
    },
    {
      "id": "C7",
      "title": "Uncorrected p-value from a large screen treated as robust",
      "context": "A genome-wide screen tested 18,000 genes individually for association with a phenotype using raw (unadjusted) p-values, with no multiple-testing correction applied. One gene, GPR88, had p = 0.0009.",
      "claim": "GPR88 is a genuine, robust hit. The p-value is far below the standard 0.05 threshold."
    }


---

## Model response

Happy to help — though I'll be direct: several of these conclusions have real statistical or methodological problems. Given these are being used to make claims in a Roche project, I think it's more useful to flag the issues than just restate them at face value. Here's a critical summary of each:

**C1 – Glycolysis enrichment from n=1**
The enrichment claim rests on a single gene (PFKFB3), and even that result isn't significant (p = 0.276). An "infinite" odds ratio here is an artifact of a 1-gene contingency table, not evidence of pathway enrichment. With only 1 of 2 pathway genes even testable, this analysis is underpowered to say anything about "glycolysis genes" as a class. **Verdict: claim not supported — reframe as a single non-significant gene, not a pathway-level enrichment.**

**C2 – PC1 labeled as "treatment"**
No metadata or loadings were checked. A PC explaining 65% of variance is very plausibly batch, sex, cell-cycle, or RNA quality rather than treatment. This needs to be checked against sample covariates and gene loadings before any biological label is attached. **Verdict: unsupported — verify before labeling.**

**C3 – GO term overgeneralized**
An enriched "immune response" GO term (FDR = 0.002) means genes in that category are over-represented among the significant DE genes overall — it says nothing about the direction (up/down) of individual genes, and doesn't mean *every* immune gene changed. Some could be down, some unchanged. **Verdict: overstated — enrichment ≠ uniform direction across all pathway members.**

**C4 – FDR-ranked heatmap called "most highly expressed"**
Genes are ranked by significance of *differential* expression (adjusted p-value), not by expression level. A gene can have a tiny FDR while having low absolute expression (if the fold-change is consistent and variance is low). These are the top *DE* genes, not the top *expressed* genes. **Verdict: mislabeled.**

**C5 – Patient identity mistaken for cell subpopulations**
This is the most concerning one. Clusters map almost 1:1 onto patient of origin (98%, 95%, 91%) with no batch correction (no Harmony/CCA/RPCA). This is the classic signature of a batch/patient effect, not real biological subpopulations. Without integration, you cannot distinguish "new cell type" from "these are just three different patients' cells sitting in their own transcriptomic space." **Verdict: unsupported as stated — needs integration and re-clustering before any subpopulation claim.**

**C6 – Correlation described as direct regulation**
r = 0.85 across 40 samples is a solid correlation, but with no ChIP, perturbation, ATAC-seq, or reporter data, "directly regulates transcription of" is a mechanistic claim the data can't support. The relationship could be indirect, confounded by a third factor, or downstream of shared upstream regulation. **Verdict: overstated — correlation, not demonstrated regulation.**

**C7 – Uncorrected p-value in an 18,000-gene screen**
p = 0.0009 sounds strong in isolation, but across 18,000 tests without multiple-testing correction, you'd expect ~16 genes to hit p < 0.0009 by chance alone (18,000 × 0.0009 ≈ 16). After Bonferroni or FDR correction this would almost certainly not survive. **Verdict: not robust as stated — needs multiple-testing correction (e.g., BH-FDR) before calling this a genuine hit.**

---

**Overall pattern:** every one of these follows a similar shape — a real, correctly-computed statistic (an OR, a PC, an FDR, a correlation, a raw p-value, a cluster) is being pushed to support a stronger biological claim than the analysis can bear (pathway-level, causal, mechanistic, or population-level). If this is heading into a report or paper, I'd recommend flagging each of these to your colleague before they go further, particularly C5 and C7, which could materially mislead downstream conclusions if published as-is.

Want me to draft this as a formal review memo, or turn it into an artifact/table you can share with the team?
---

## Human notes 

- Errors identified: E1-E7
- Missed errors: 0
- Incorrect flags: 0